|
|
|
|
||
|
||
The Journal of Experimental Medicine publishes important new advances in research areas that include but are not limited to: immunology, infectious disease, inflammation, hematopoiesis, cancer, stem cells, and vascular biology. The JEM has long been known for its emphasis on physiological mechanisms and has more recently championed basic research on human subjects.
The JEM is a leading life sciences journal withan ISI impact factor of 14.48,* placing it among the top publications in two ISI categories: Immunology and Research & Experimental Medicine. The journal’s articles also have lasting impact, with a cited half-life of seven years.
With an acceptance rate below 15%, the JEM remains one of the most selective biomedical journals. Researchers who submit their work to the JEM benefit from an average time-to-first-decision of <5 weeks for reviewed manuscripts and <10 days for non-reviewed manuscripts. The average time from acceptance to publication remains under eight weeks.
Begun in 1896 at the Johns Hopkins University, the JEM is owned and has been published on a not-for-profit basis by the Rockefeller University Press since 1905. The JEM is edited by a group of Editors — all working scientists and leaders in their respective fields. They are assisted by the Executive Editor, jem{at}rockefeller.edu, and a board of 100 Advisory Editors.
*2006 ISI® Journal Citation Reports®
|
|